Clinical trial
Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
NCT00220701 · St. Luke's-Roosevelt Hospital Center, Other · Completed
Key facts
| NCT number | NCT00220701 |
|---|---|
| Title | Escitalopram in the Treatment of Dysthymic Disorder, Double Blind |
| Official title | Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder |
| Lead sponsor | St. Luke's-Roosevelt Hospital Center, Other |
| Collaborators | Forest Laboratories Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Dysthymic Disorder |
| Intervention type | Drug |
| Interventions | Lexapro (escitalopram) |
| Enrollment | 36 |
| Start date | Jun 1, 2002 |
| Primary completion | Nov 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 11, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: